| abstract |
The present invention relates to a method for diagnosing or prognosing metastasis in lung cancer, comprising the step of ascertaining whether the c-MAF gene is amplified in a primary tumor sample. The present invention also relates to a method for measuring the tendency to develop bone metastasis relative to metastasis in other organs, including the step of diagnosing or prognosing metastasis in lung cancer, as well as measuring the c-MAF gene expression level will be. Finally, the present invention relates to the use of a c-MAF inhibitor as a therapeutic target for treating lung cancer. |